JC-1|CAS 3520-43-2|DC Chemicals

Cas No.:	3520-43-2
Chemical Name:	1H-Benzimidazolium, 5,6-dichloro-2-(3-(5,6-dichloro-1,3-diethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)-1-propenyl)-1,3-diethyl-, iodide
Synonyms:	JC 1; JC-1; JC1
SMILES:	CC[N+]1=C(/C=C/C=C2N(CC)C3=CC(Cl)=C(Cl)C=C3N\2CC)N(CC)C4=CC(Cl)=C(Cl)C=C14.[I-]
Formula:	C₂₅H₂₇Cl₄In₄
M.Wt:	652.2235
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	1. Abdalah, R., Wei, L., Francis, K., et al. Valinomycin-induced apoptosis in Chinese hamster ovary cells. Neuroscience Letters 405, 68-73 (2006). 2. Petit, P.X., Lecoeur, H., Zorn, E., et al. Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. Journal of Cell Biology 130(1), 157-167 (1995). 3. Salvioli, S., Ardizzoni, A., Franceschi, C., et al. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess Δψ changes in intact cells: Implications for studies on mitochondrial functionality during apoptosis. FEBS Letters 411, 77-82 (1997).

Description:	JC-1 is a fluorescent lipophilic carbocyanine dye used to measure mitochondrial membrane potential.
In Vitro:	JC-1 (2.5 μM) exposed to murine L1210 lymphoblasts, can be detected the presence of both cytoplasmic JC-1 monomer and mitochondrial J-aggregates in these cells. JC-1 fluorescence is usually excited by the 488 nm laser wavelength common in flow cytometers[1]. Fluorescent labeling of mitochondria with either JC-1 (1 μg/mL, 15 min), reveals that are distributed irregularly, resulting in regions of high and low mitochondrial content within astrocytes[2]. JC-1 has been shown to interact with α-synuclein at the acidic C-terminal region with a Kd of 2.6 μM. JC-1 itself does not accelerate the protein aggregation of α-synuclein in the absence of iron, insted, it decelerates the aggregation process by extending the lag phase approx[3]. JC-1 is avidly accumulated in sensitive K562 cells where it displays both a green cytoplasmic and red mitochondrial fluorescence. JC-1 is poorly accumulated in resistant K562 cells, which displays only a slight green fluorescence[4].
References:	[1]. A Perelman, et al. JC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry. Cell Death Dis. 2012 Nov 22;3:e430. [2]. Vera C. Keil, et al. Ratiometric high-resolution imaging of JC-1 fluorescence reveals the subcellular heterogeneity of astrocytic mitochondria. Pflügers Archiv - European Journal of Physiology. 2011,462(5): 693-708. [3]. Jung-Ho LEE, In-Hwan LEE, Young-Jun CHOE, et al. Real-time analysis of amyloid fibril formation of α-synuclein using a fibrillation-state-specific fluorescent probe of JC-1. Biochem. J. 2009, 418:311-323. [4]. Salvioli S, et al. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett. 1997 Jul 7;411(1):77-82.

Cat. No.	Product name	Field of application
DC60859	MT-125(MT 125)	MT125 is a brain-penetrant small-molecule inhibitor selectively targeting non-muscle myosin IIA/B (NMIIA/B) with >20-fold specificity over cardiac myosin. It demonstrates potent anti-glioblastoma activity by: (1) blocking tumor invasion and cytokinesis (inducing polyploidy), (2) disrupting mitochondrial dynamics to elevate ROS and trigger ferroptosis, and (3) sensitizing tumors to radiotherapy/kinase inhibitors via ROS-driven PDGFR/mTOR pathway activation. Subcutaneous administration achieves brain concentrations twice plasma levels (t_1/2~10.5 hr) with no toxicity observed at 15× the therapeutic dose in rats. MT-125 monotherapy extends survival in GBM models, while combinations with PDGFR/PI3K inhibitors induce long-term remission (>40% mice). Its first-in-class mechanism, safety profile, and CNS bioavailability support clinical development for glioblastoma.
DC60781	TRPC6 activator compound 2	TRPC6 activator compound 2 is selective activator of TRPC6 that does not potentiate TRPC3 and mTRPC7. Comp2 is able to cross BBB.
DC66546	R-Sirpiglenastat	R-Sirpiglenastat is the R- isomer of Sirpiglenastat(DRP-104).Sirpiglenastat (DRP104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response.
DC60597	AZD0780	AZD0780 is the first oral small molecule PCSK9 inhibitor for the treatment of hypercholesterolemia.
DC90056	PLX-5622 HCl form (water solubility form)	PLX5622 is the HCl salt form of PLX-5622, which has better water solubility.PLX-5622 is a highly selective brain-penetrant CSF1R inhibitor (IC50=0.016 µM; Ki=5.9 nM) allowing for extended and specific microglial elimination, preceding and during pathology development.
DC65830	1-M-PES(1-Methoxy-5-methylphenazinium ethyl sulfate)	1-m-PES is an electron mediator which has higher stability of solutions than 1-Methoxy PMS. The stability in neutral to alkali conditions has been extremely improved with 1-Methoxy PES. 1-M-PES is a stable small-molecular compound and it has an equal or higher thermal stability than diaphorase. The 1-Methoxy PES solution can be stored long term.
DC65821	Upadacitinib hemihydrate	Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM, being developed for the treatment of several autoimmune disorders.
DC65697	HDAC6 inhibitor 4510	A novel and seletive HDAC6 inhibitor.
DC65676	Fenretinide Glucuronide Monosodium Salt	Fenretinide Glucuronide Monosodium Salt, is the metabolite of Fenretinide (F250000), which is a synthetic retinoid deriverative, substances related to vitamin A. They are also shown to be used for the treatment of cancer, as well as in the treatment of cystic fibrosis, rheumatoid arthritis, acne, and psoriasis.
DC89083	Pacritinib citrate	Pacritinib Citrate is the citrate salt form of pacritinib, an orally bioavailable inhibitor of Janus kinase 2 (JAK2).